A multicenter phase Ib/II study of DNA-PK inhibitor peposertib (M3814) in combination with capecitabine and radiotherapy in patients with locally advanced rectal cancer. Background: Although most ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback